Osteoporosis – Pipeline Review, H1 2018
- Pages: 251
- Published: April 2018
- Report Code: GMDHC10379IDB
Global Markets Direct’s, ‘Osteoporosis – Pipeline Review, H1 2018’, provides an overview of the Osteoporosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Osteoporosis
– The report reviews pipeline therapeutics for Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Osteoporosis therapeutics and enlists all their major and minor projects
– The report assesses Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Osteoporosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Osteoporosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Abreos Biosciences Inc
Alvogen Korea Co Ltd
Amgen Inc
Asahi Kasei Corp
BiologicsMD Inc
Bone Biologics Corp
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Cellmid Ltd
ChoDang Pharm Co Ltd
Chugai Pharmaceutical Co Ltd
Corium International Inc
Daiichi Sankyo Co Ltd
Dong Wha Pharma Co Ltd
ElexoPharm GmbH
Eli Lilly and Co
EndoCeutics Inc
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Evgen Pharma Plc
Gador SA
GL Pharm Tech Corp
GlycoNex Inc
Hanmi Pharmaceuticals Co Ltd
Haoma Medica Ltd
Huons Global Co Ltd
Immunovo BV
Immunwork Inc
Intas Pharmaceuticals Ltd
Ipsen SA
JHL Biotech Inc
Kaken Pharmaceutical Co Ltd
Lead Discovery Center GmbH
Lotus Pharmaceutical Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
mAbxience SA
Merck & Co Inc
Millendo Therapeutics Inc
NIBEC
Omeros Corp
Oncobiologics Inc
Paras Biopharmaceuticals Finland Oy
Pfenex Inc
PhytoHealth Corp
R Pharm
Ribomic Inc
Richter Gedeon Nyrt
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shin Poong PharmCo Ltd
Sinil Pharmaceutical Co Ltd
Stelis Biopharma Pvt Ltd
Terpenoid Therapeutics Inc
TSH Biopharm Corporation Ltd
Uni-Bio Science Group Ltd
Viking Therapeutics Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Yooyoung Pharm Co Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.